Date published: 2025-10-17

1-800-457-3801

SCBT Portrait Logo
Seach Input

CEI Inhibitors

In the complex landscape of cellular signaling, inhibitors of the CEI protein function through various mechanisms to impede its activity. Kinase inhibitors exert their effects by targeting kinases that are either directly phosphorylating CEI or are part of the signaling cascade that regulates its activity. By obstructing these kinases, the phosphorylation status of CEI can be altered, leading to a reduction in its functional activity. Similarly, inhibitors targeting the MEK/ERK and PI3K/AKT pathways play a critical role in modulating CEI activity. These inhibitors work by disrupting the signaling processes upstream of CEI, which, if CEI is a downstream effector, would result in a decrease in its activation state. The delicate interplay between these pathways is crucial for maintaining CEI's functionality, and the perturbation of these pathways by specific inhibitors can hinder CEI's role in cellular processes.

Additionally, the inhibition of mTOR signaling through certain compounds can indirectly suppress CEI activity, considering mTOR's role in regulating various proteins that may interact with or control CEI. Proteasome inhibitors may also contribute to the downregulation of CEI by stabilizing proteins that negatively regulate it, thus creating an environment where CEI's activity is curtailed. Furthermore, immunosuppressive agents that inhibit calcineurin could reduce CEI activity by affecting signaling pathways that converge on the modulation of CEI, including the prevention of necessary dephosphorylation events. Compounds that modulate the stability of transcription factors likewise play a role in the indirect inhibition of CEI, as they can alter the gene expression of proteins that regulate CEI's activity, leading to a decrease in CEI's capacity to function within the cell.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

A potent kinase inhibitor that by inhibiting a variety of kinases downstream or upstream could reduce CEI phosphorylation and thereby its activity.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

A selective inhibitor of MEK which in turn blocks ERK pathway activation, potentially reducing CEI activity if CEI is a downstream effector of this pathway.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

A PI3K inhibitor that impairs the PI3K/AKT pathway, which may lead to a reduction in CEI activity if CEI is involved in this signaling cascade.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

A JNK inhibitor which could impede CEI activity by disrupting JNK-mediated signal transduction processes in which CEI is implicated.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

A p38 MAPK inhibitor that can decrease CEI activity by inhibiting a pathway that may modulate CEI function or expression.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

A selective inhibitor of MEK1/2 which may lead to decreased CEI activity by blocking the MAPK/ERK pathway if CEI is regulated by this signaling axis.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

An inhibitor of PI3K, leading to the downregulation of the AKT pathway which could decrease CEI activity if CEI functions upstream or downstream of AKT.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

An mTOR inhibitor which could suppress CEI activity by influencing mTOR-related pathways that regulate CEI function or stability.

Triciribine

35943-35-2sc-200661
sc-200661A
1 mg
5 mg
$102.00
$138.00
14
(1)

An AKT inhibitor that potentially reduces CEI activity by impairing a pathway in which CEI acts downstream of AKT signaling.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

A proteasome inhibitor which could lead to decreased CEI activity through stabilization of proteins that negatively regulate CEI or its associated pathways.